These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18556978)

  • 1. Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.
    Aggermann T; Haas P; Binder S
    Ann Ophthalmol (Skokie); 2008; 40(1):28-30. PubMed ID: 18556978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First clinical experience with anecortave acetate (Retaane).
    Hayek S; Scherrer M; Barthelmes D; Fleischhauer JC; Kurz-Levin MM; Menghini M; Helbig H; Sutter FK
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):279-81. PubMed ID: 17458792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study.
    Klais CM; Eandi CM; Ober MD; Sorenson JA; Sadeghi SN; Freund KB; Spaide RF; Slakter JS; Yannuzzi LA
    Retina; 2006 Sep; 26(7):773-9. PubMed ID: 16963850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes.
    Russell SR; Hudson HL; Jerdan JA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S79-90. PubMed ID: 17240260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger DS; Luna SP; Robertson SM; Russell S; Singerman L; Slakter JS; Yannuzzi L; Zilliox P;
    Ophthalmology; 2003 Dec; 110(12):2372-83; discussin 2384-5. PubMed ID: 14644721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical efficacy of anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S41-8. PubMed ID: 17240256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Schmidt-Erfurth U; Michels S; Michels R; Aue A
    Eur J Ophthalmol; 2005; 15(4):482-5. PubMed ID: 16001382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger S; Luna S; Robertson SM; Russell S; Singerman L; Slakter JS; Sullivan EK; Yannuzzi L; Zilliox P;
    Retina; 2003 Feb; 23(1):14-23. PubMed ID: 12652226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration.
    Augustin AJ; D'Amico DJ; Mieler WF; Schneebaum C; Beasley C
    Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):9-12. PubMed ID: 15290154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
    Retina; 2007; 27(4):439-44. PubMed ID: 17420695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anecortave acetate.
    Clarke MS
    Ophthalmology; 2004 Dec; 111(12):2316; author reply 2316-7. PubMed ID: 15582099
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.